A MULTIDISCIPLINARY EVENT FOR PHYSICIANS/PROVIDERS

Physicians and providers working in the lung cancer space will gather to identify solutions for the barriers that keep approximately half of Minnesota’s eligible patients from receiving critical biomarker testing to determine their optimal treatment.

Providers – please plan to join A Breath of Hope and the MN lung cancer medical community for the second annual Minnesota Biomarker Summit. The event will be held in Edina, MN, on Friday, October 24th from 8 a.m. to noon. Networking meals will be available at 7 a.m. and noon. There is no cost for providers to attend this event. Register below.

Along with a dedicated group of lung cancer experts from healthcare systems in MN, ABOH will host this multidisciplinary team summit to engage and update oncologists, pathologists, thoracic surgeons and other medical professionals who are responsible within their system for making decisions about treatments or ordering biomarker testing for newly diagnosed lung cancer patients. NOTE: A similar event will be held on Friday, June 6 in Duluth for rural providers.

Tentative Agenda

The How and Why of Biomarker Testing/US Guidelines/Tissue & Liquid Biopsies – Minnesota Pathologists (with tabletop discussions to follow)

Practical Strategies to Overcome Barriers to Biomarker Testing for NSCLC Patients – Panel of physicians from six healthcare systems serving Minnesotans

• • Jaime Schneider, MD, PhD, Medical Oncologist, Assistant Professor of Medicine, Harvard Medical School.
  • Naomi Fujioka, MD, Medical Oncologist, Associate Professor, University of Minnesota Medical School.
  • Bob Kratzke, MD, Medical Oncologist, Professor, Department Chair, University of Minnesota Medical School.
  • Manish Patel, DO, Medical Oncologist, Associate Professor, University of Minnesota Medical School.
  • Joe Leach, MD, Medical Oncologist, Associate Medical Director, Quality and Safety. Allina Health Cancer Institute.
  • Ying-Chun Lo, MD, PhD, Pathologist, Mayo Clinic
  • Other speakers TBD

The Value of Broad Panels that Capture Actionable and Non-Actionable Mutations (with tabletop discussions to follow)

• • Working Through Reports on Actionable Lung Cancer Biomarkers/Available Targeted Therapies
  • Non-actionable Mutations that may influence clinical decision making (i.e. TP53 in EGFR patients or STK11/KEAP1)

VIEW SPONSOR CHART – scroll below for our generous sponsors!

PROVIDERS: Register below to hold your spot

THANK YOU EXHIBITORS!

PARTNER ($20,000)

CONTRIBUTOR ($5,000)

PATRON ($2,500)